A recent toast to James Watson highlights a tolerance for bigotry many want excised from the scientific community.
The blood-brain barrier is a collection of specialized cells and proteins that control the movement of molecules from the blood to the central nervous system.
November 1, 2017|
The blood vessel endothelial cells of the BBB are cemented together by protein structures called tight junctions (1), preventing diffusion of most molecules between cells. BBB endothelial cells display transporters (2), receptors (3), and channels (4) that facilitate selective transport of vital nutrients into the CNS. They also possess efflux pumps, such as P-glycoprotein, that expel most small, amphiphilic molecules that are soluble in the blood and in cell lipid membranes (5). Pericytes and astrocyte pseudopods serve as an additional physical barrier between the blood vessel and brain tissue, and support the expression of endothelial cell genes required to maintain the BBB.
© 2017, LISA CLARK
Designing drugs to reach the CNS requires some creativity on the part of researchers. The approaches vary from disrupting the BBB’s tight junctions with ultrasound waves and microbubbles to hijacking the barrier’s own transport systems. Each technique comes with its benefits and drawbacks, making it appropriate for some patients or drug types but not others.
© 2017, LISA CLARK(A) Convection-enhanced delivery: Catheters placed in the brain through a hole in the skull allow the passage of even large drugs. Pressure is used to infuse a drug as evenly as possible into a specified region of the brain.
(B) Opening the BBB: After injecting microbubbles into a patient’s bloodstream, researchers apply low-energy ultrasound waves that cause the bubbles to swell and contract. This oscillation weakens the BBB and reduces the abundance of tight junction proteins, reversibly opening the barrier to allow the delivery of a drug from the blood to a targeted region of the brain.
(C) Passing the pumps: Amphiphilic compounds—those that are soluble in the blood and in cell lipid membranes—can reach the CNS by entering and exiting BBB endothelial cells. Most of these molecules are expelled from the endothelial cells back into the bloodstream through efflux pumps. To get around this barrier, researchers alter drugs to avoid binding to such pumps or use compounds that hinder pump activity.
(D) Traversing receptors or transporters: Drug designers can tailor compounds to bind one of the many receptors or transporters that BBB endothelial cells use to supply the brain with nutrients and essential molecules such as amino acids. The drug could be covered with a natural substrate of one of these receptors or engineered to bind both a BBB endothelial cell receptor and its target within the CNS.
(E) Osmotic diuretics: When solutions of diuretics are injected into the carotid artery, they draw fluid out of BBB endothelial cells, causing the cells to shrink. This leaves gaps between the endothelial cells, granting small and large molecules indiscriminate access to the entire brain for minutes to hours.
(F) Intranasal delivery: Drugs can also reach the CNS through the nose. Researchers are still studying the exact mechanism behind this transport, but compounds seem to be able to travel though the extracellular space surrounding the olfactory nerves, ending up in the cerebral spinal fluid.
Read the full story.
November 30, 2017
What about the recent rediscovery of a lympatic system in human brains? https://en.wikipedia.org/wiki/Meningeal_lymphatic_vessels
November 30, 2017
We've written about that discovery: https://www.the-scientist.com/?articles.view/articleNo/43120/title/Brain-Drain/
And also more in detail on new insights into lymphatics development: https://www.the-scientist.com/?articles.view/articleNo/43550/title/Rethinking-Lymphatic-Development/
Thank you for reading.
Kerry Grens, Senior Editor